Baillie Gifford & CO Heron Therapeutics, Inc. Transaction History
Baillie Gifford & CO
- $128 Billion
- Q3 2025
Shares
2 transactions
Others Institutions Holding HRTX
# of Institutions
188Shares Held
151MCall Options Held
20.1KPut Options Held
2.12M-
Rubric Capital Management LP New York, NY29.1MShares$32 Million0.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA10.2MShares$11.3 Million0.02% of portfolio
-
Clearline Capital LP New York, NY9.71MShares$10.7 Million0.62% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA8.75MShares$9.63 Million21.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.46MShares$9.31 Million0.0% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $131M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...